Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : Structural Genomics Consortium
Deal Size : Undisclosed
Deal Type : Partnership
Details : As part of the initiative, the SGC and Cyclica examined three WDR proteins to discover small molecule binders using Cyclica’s proprietary deep learning platform to assess commercially available libraries for potential binders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 11, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : Structural Genomics Consortium
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
Details : AbCellera has expanded its collaboration with Gilead Sciences to include a multi-year, multi-target antibody discovery deal and access to AbCellera’s humanized mouse technology, the Trianni Mouse®.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
January 04, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
AbCellera Announces Multi-Year Antibody Discovery Collaboration with Lilly
Details : AbCellera will use its world-leading antibody drug discovery platform in a multi-year collaboration to identify antibodies against up to nine targets.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
May 22, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : Government of Canada
Deal Size : $175.6 million
Deal Type : Funding
Details : Fund will expand AbCellera's efforts, as more than 500 specific human anti-SARS-CoV-2 antibodies have been established as part of a partnership with the Vaccine Research Center.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 05, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : Government of Canada
Deal Size : $175.6 million
Deal Type : Funding